Doral Fredericks
YOU?
Author Swipe
View article: Efficacy Outcomes in Clinical Trials of Atopic Dermatitis Treatments: A Systematic Literature Review
Efficacy Outcomes in Clinical Trials of Atopic Dermatitis Treatments: A Systematic Literature Review Open
Introduction: Complete skin clearance is a key atopic dermatitis (AD) treatment goal. Treatment efficacy in AD trials is evaluated using a range of clinical measures with the Investigator’s Global Assessment (IGA) as a key endpoint. Multip…
View article: The organisational response of a hospital critical care service to the COVID-19 pandemic: The Groote Schuur Hospital experience
The organisational response of a hospital critical care service to the COVID-19 pandemic: The Groote Schuur Hospital experience Open
We describe the organisational requirements to successfully expand critical care facilities and strategies to reduce the need for invasive mechanical ventilation in COVID-19 pneumonia. We also present the intensive care outcomes of these p…
View article: Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications Open
Background : PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms. Objective : To evaluate the differential effect of the antipsychotic pimavans…
View article: 135 Use of Pimavanserin in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs)
135 Use of Pimavanserin in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) Open
Study Objective Psychosis is common in Parkinson’s disease (PD) and increases in both frequency and severity with disease duration. It is associated withincreased morbidity/mortality, complicates management of motor symptoms and often lead…
View article: 122 Use of Pimavanserin in Patients With Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment
122 Use of Pimavanserin in Patients With Parkinson’s Disease Psychosis: Subgroup Analysis of Efficacy and Safety in Patients With and Without Cognitive Impairment Open
Objective A planned subgroup analysis of a phase 3 study was performed to evaluate the efficacy and safety of pimavanserin (PIM) in Parkinson’s disease psychosis (PDP) patients withglobal cognitive impairment. Background PDP is frequent, d…
View article: Parkinson’s Disease Psychosis – Prevalence Patterns Across the EU-5
Parkinson’s Disease Psychosis – Prevalence Patterns Across the EU-5 Open
Parkinson’s disease psychosis (PDP) is a clinical condition that affects patients diagnosed with Parkinson’s disease (PD) and has a spectrum of neuropsychiatric symptoms distinct from the hallmark motor symptoms. Although prior studies hav…
View article: Parkinson’s Disease Psychosis – Patterns of Care and Treatment in the EU-5 from Neurologists’ Perspective
Parkinson’s Disease Psychosis – Patterns of Care and Treatment in the EU-5 from Neurologists’ Perspective Open
Over half of patients with Parkinson’s disease (PD) develop symptoms of psychosis during the course of their disease. Existing guidelines include recommendations for managing symptoms of psychosis in patients with PD. However, the extent t…